Skip to main navigation
Caladrius
Caladrius
  • Contact Us
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Chronic Kidney Disease (CKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Careers
    • Overview
    • Job Opportunities
  • Investors & News
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
      • Media Coverage
    • Financials & Filings
      • Quarterly Results
      • SEC Filings
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Corporate Governance
      • Docs & Charters
      • Management
      • Board of Directors
    • Investor Resources
      • Stockholder Information
      • Investor FAQs
      • Email Alerts
      • IR Contact
      • Disclosures
  • Patients & Families
    • Overview
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia Symptoms & Treatment
  • Careers
    • Overview
    • Job Opportunities
Investors & News / Financials & Filings / Investors & News / SEC Filings / D /

SEC Filing Details

Document Details

Form
D
Filing Date
Feb 1, 2021
Document Date
Feb 1, 2021
Filing Group
Other
Company
Caladrius Biosciences, Inc.
Issuer
CALADRIUS BIOSCIENCES, INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS
  • Print Page
  • RSS Feeds
  • Email Alerts
Caladrius
Caladrius
Active Clinical Trials
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Pipeline
    • Overview
    • Coronary Microvascular Dysfunction (CMD) XOWNA®
    • Critical Limb Ischemia (CLI) CLBS12 (HONEDRA® in Japan)
    • Chronic Kidney Disease (CKD) CLBS201
    • No-Option Refractory Disabling Angina (NORDA) CLBS14 (OLOGO™ in the USA)
  • Research & Technology
    • Overview
    • CD34+ Cell Technology
    • Publications
  • Careers
    • Overview
    • Job Opportunities
  • Investors & News
    • Overview
    • News & Events
    • Financials & Filings
    • Stock Information
    • Corporate Governance
    • Investor Resources
  • Patients & Families
    • Overview
    • Coronary Microvascular Dysfunction Symptoms & Treatment
    • Critical Limb Ischemia Symptoms & Treatment
  • Careers
    • Overview
    • Job Opportunities
  • Facebook
  • Twitter
  • LinkedIn
Join Our Email List

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100

© 2022 Caladrius Biosciences, Inc. All rights reserved.
  • Site Map
  • Privacy Policy

110 Allen Road, 2nd Flr, Basking Ridge, NJ 07920|Telephone 908.842.0100